Sign Language as an Alternative Communication Modality for Children with Autism Spectrum Disorder: A Qualitative Exploration
PISER JOURNAL · 01.12.2025 · 2 (1)
DOI: 10.66191/pjv2.202508 ↗Kurz gefasst
Fachartikel in der Zeitschrift PISER JOURNAL, online erschienen am 01.12.2025. Verfasst von Ruksana Baset.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
This study explores the effectiveness of sign language as an alternative communication method for children with autism spectrum disorder (ASD), focusing on nonverbal and minimally verbal participants. Conducted at Proyash Institute of Special Education in Dhaka, Bangladesh, the qualitative study involved eight boys aged 8-14 who received sign language instruction over eight sessions. The intervention emphasized six functional signs using visual aids and reinforcement techniques. Results showed that half the participants acquired all or some of the signs, particularly those with stronger cognitive and attentional skills. However, parental misconceptions-such as fears that sign language might hinder speech development-emerged as a key barrier to implementation. Despite limitations related to sample size and scope, the study supports sign language as a viable augmentative communication strategy for children with ASD and highlights the need to engage parents through awareness-building and support.
Zitieren
APA
Baset, R. (2025). Sign Language as an Alternative Communication Modality for Children with Autism Spectrum Disorder: A Qualitative Exploration. PISER JOURNAL, 2(1). https://doi.org/10.66191/pjv2.202508
Vancouver
Baset R. Sign Language as an Alternative Communication Modality for Children with Autism Spectrum Disorder: A Qualitative Exploration. PISER JOURNAL. 2025;2(1). doi:10.66191/pjv2.202508
BibTeX
@article{Baset2025,
author = {Baset, Ruksana},
title = {Sign Language as an Alternative Communication Modality for Children with Autism Spectrum Disorder: A Qualitative Exploration},
journal = {PISER JOURNAL},
year = {2025},
volume = {2},
number = {1},
doi = {10.66191/pjv2.202508}
}
EUVIMED